Baxter Launches Arisure Closed System Transfer Device to Help Prevent Hazardous Drug Exposure and Maintain Medication Sterility
January 11 2018 - 8:33AM
Business Wire
- Helps ensure safer drug preparation,
transportation, administration and disposal
- Helps support compliance with NIOSH and
upcoming USP <800> standards
Baxter International Inc. (NYSE: BAX), a leader in innovative
technology for medication delivery, today announced a distribution
agreement for the U.S. launch of the Arisure Closed System Transfer
device, which consists of several components that work together to
help prevent contaminants from entering the intravenous (IV)
medication delivery system and the escape of hazardous substances
out of the system during drug preparation and administration.
The Arisure Closed System Transfer device is designed to be easy
to use with an emphasis on safety. The device includes a closed
vial adapter that helps provide closed access to liquid or powder
vials for reconstitution; an intravenous dry spike that helps
provide closed access to an IV bag for addition and removal of a
drug or solution; and a closed male Luer valve that helps provide
closed transfer of a diluent or drug from a standard male Luer tip
in a syringe or administration set. The Arisure Closed Male Luer
locks with a simple Luer lock motion on a syringe or administration
set, helping reduce the exposure of healthcare professionals to
sharp needles. In addition, the Arisure Closed Male Luer components
are compatible with Baxter’s ONE-LINK Needle-free IV Connector and
CLEARLINK Luer Activated Valve to help create a mechanically and
microbiologically closed system.
“The Arisure Closed System Transfer device helps address
multiple concerns of both healthcare professionals and patients,
helping ensure safer drug preparation, transportation,
administration and disposal, and helping reduce the risk of
accidental exposure or contamination,” said Scott Luce, general
manager, U.S. Hospital Products, Baxter. “In addition, this
technology will help hospitals comply with professional standards
for safe handling of hazardous drugs.”
Currently, the National Institute for Occupational Safety and
Health (NIOSH) recommends closed-system drug transfer devices, and
the United States Pharmacopeia (USP) is expected to introduce USP
General Chapter <800>, detailing its standards for safe
handling of hazardous drugs, in December 2019.
The Arisure Closed System Transfer device is the latest addition
to Baxter’s broad portfolio of products designed to help enhance
the safe delivery of medication across the patient continuum of
care, from the pharmacy to the bedside. These products include but
are not limited to pharmacy software and automation that helps
promote dose preparation safety and reduce waste; the Sigma
Spectrum Infusion System that includes pioneering safety
features to help minimize patient risk when administering vital
fluids and medications; and needle-free connector product lines
that can contribute to reducing hospital infections.
About Baxter
Baxter provides a broad portfolio of essential renal and
hospital products, including home, acute and in-center dialysis;
sterile IV solutions; infusion systems and devices; parenteral
nutrition; surgery products and anesthetics; and pharmacy
automation, software and services. The company’s global footprint
and the critical nature of its products and services play a key
role in expanding access to healthcare in emerging and developed
countries. Baxter’s employees worldwide are building upon the
company’s rich heritage of medical breakthroughs to advance the
next generation of healthcare innovations that enable patient
care.
This release includes forward-looking statements concerning the
Arisure Closed System Transfer device, including potential benefits
associated with its use (including helping to ensure safer drug
preparation, transportation, administration and disposal). The
statements are based on assumptions about many important factors,
including the following, which could cause actual results to differ
materially from those in the forward-looking statements:
satisfaction of regulatory and other requirements; actions of
regulatory bodies and other governmental authorities; product
quality, manufacturing or supply, or patient safety issues; changes
in law and regulations; and other risks identified in Baxter's most
recent filing on Form 10-K and other SEC filings, all of which are
available on Baxter's website. Baxter does not undertake to update
its forward-looking statements.
Rx Only. For safe and proper use of this device, refer to
the full Instructions for Use.
Baxter, ONE-LINK, CLEARLINK and Sigma Spectrum are
trademarks of Baxter International Inc.
Arisure is a trademark of Yukon Medical, LLC.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180111005529/en/
Baxter International Inc.Media ContactEric Tatro, (224)
948-5353media@baxter.comorInvestor ContactClare Trachtman,
(224) 948-3085
Baxter (NYSE:BAX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Baxter (NYSE:BAX)
Historical Stock Chart
From Apr 2023 to Apr 2024